Raloxifene Hydrochloride (Page 7 of 9)

14.4 Reduction in Risk of Invasive Breast Cancer in Postmenopausal Women at High Risk of Invasive Breast Cancer

STAR Trial

The effects of raloxifene HCl 60 mg/day versus tamoxifen 20 mg/day over 5 years on reducing the incidence of invasive breast cancer were assessed in 19,747 postmenopausal women in a randomized, double-blind trial conducted in North America by the National Surgical Adjuvant Breast and Bowel Project and sponsored by the National Cancer Institute. Women in this study had a mean age of 58.5 years (range 35 to 83), a mean 5-year predicted invasive breast cancer risk of 4.03% (range 1.66% to 23.61%) and 9.1% had a history of lobular carcinoma in situ (LCIS). More than 93% of participants were White. As of 31 December 2005, the median time of follow-up was 4.3 years (range 0.07 to 6.50 years).

Raloxifene HCl was not superior to tamoxifen in reducing the incidence of invasive breast cancer. The observed incidence rates of invasive breast cancer were raloxifene HCl 4.4 and tamoxifen 4.3 per 1000 women per year. The results from a noninferiority analysis are consistent with raloxifene HCl potentially losing up to 35% of the tamoxifen effect on reduction of invasive breast cancer. The effect of each treatment on invasive breast cancer was consistent when women were compared by baseline age, history of LCIS, history of atypical hyperplasia, 5-year predicted risk of breast cancer by the modified Gail model, or the number of relatives with a history of breast cancer. Fewer noninvasive breast cancers occurred in the tamoxifen group compared to the raloxifene HCl group. Table 9 presents efficacy and selected safety outcomes.

Table 9: Raloxifene HCl (60 mg Once Daily) vs. Tamoxifen (20 mg Once Daily) on Outcomes in Postmenopausal Women at Increased Risk for Invasive Breast Cancer
Raloxifene HCl (N=9751) Tamoxifen (N=9736) RR (95% CI) a
Outcomes n IR a n IR a
Invasive breast cancer 173 4.40 168 4.30 1.02 (0.82, 1.27)
ER a positive 115 2.93 120 3.07 0.95 (0.73, 1.24)
ER a negative 52 1.32 46 1.18 1.12 (0.74, 1.71)
ER a unknown 6 0.15 2 0.05 2.98 (0.53, 30.21)
Noninvasive breast cancer b 83 2.12 60 1.54 1.38 (0.98, 1.95)
DCIS a 47 1.20 32 0.82 1.46 (0.91, 2.37)
LCIS a 29 0.74 23 0.59 1.26 (0.70, 2.27)
Uterine cancer c 23 1.21 37 1.99 0.61 (0.34, 1.05)
Endometrial hyperplasia c 17 0.90 100 5.42 0.17 (0.09, 0.28)
Hysterectomy c 92 4.84 246 13.25 0.37 (0.28, 0.47)
Ovarian cancer d 18 0.66 14 0.52 1.27 (0.60, 2.76)
Ischemic heart disease e 138 3.50 125 3.19 1.10 (0.86, 1.41)
Stroke 54 1.36 56 1.42 0.96 (0.65, 1.42)
Deep vein thrombosis 67 1.69 92 2.35 0.72 (0.52, 1)
Pulmonary embolism 38 0.96 58 1.47 0.65 (0.42, 1)
Clinical vertebral fractures 58 1.46 58 1.47 0.99 (0.68, 1.46)
Cataracts f 343 10.34 435 13.19 0.78 (0.68, 0.91)
Cataract surgery f 240 7.17 295 8.85 0.81 (0.68, 0.96)
Death 104 2.62 109 2.76 0.95 (0.72, 1.25)
Edema g 741 18.66 664 16.83 1.11 (1, 1.23)
Hot flashes 6748 169.91 7170 181.71 0.94 (0.90, 0.97)
a Abbreviations: CI = confidence interval; DCIS = ductal carcinoma in situ; ER = estrogen receptor; IR = annual incidence rate per 1000 women; LCIS = lobular carcinoma in situ; RR = risk ratio for women in the raloxifene HCl group compared with those in the tamoxifen group.
b Of the 60 noninvasive breast cases in the tamoxifen group, 5 were mixed types. Of the 83 noninvasive breast cancers in the raloxifene group, 7 were mixed types.
c Only patients with an intact uterus at baseline were included (tamoxifen = 4739, raloxifene HCl = 4715).
d Only patients with at least one intact ovary at baseline were included (tamoxifen = 6813, raloxifene HCl = 6787).
e Defined as myocardial infarction, severe angina, or acute ischemic syndromes.
f Only patients who were free of cataracts at baseline were included (tamoxifen = 8342; raloxifene HCl = 8333).
g Peripheral edema events are included in the term edema.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2022. All Rights Reserved.